the firm's post-grant practitioners are some of the most experienced in the country.

Technologies

Artificial Intelligence (AI)
Artificial Intelligence (AI)
Digital Health
Digital Health
Energy & Renewables
Energy & Renewables

Fast Facts

About Our

Law Firm

About Our Law Firm

Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.

Get to know our

History

Get to know our History

1968
Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.

Our Local and

Global Reach

Our Local and Global Reach

Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.

A few of our

ACCOLADES

A few of our ACCOLADES

Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.

OPPORTUNITIES FOR YOUR

Career

OPPORTUNITIES FOR YOUR Career

From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.

A few ways to

GET In Touch

A few ways to GET In Touch
US Office

Telephone: 703-413-3000
Learn More +


Tokyo Office

Telephone: +81-3-6212-0550
Learn More +

Downloadable

Patent Forms

Downloadable Patent Forms

The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.

Stay informed with

Our Blogs

WEBINAR: Listing Medical Devices in the Orange Book After Teva v. Amneal

Schedule : Next Month

Associated People


In Teva v. Amneal the Federal Circuit joined the 1st and 2nd Circuits in holding that medical device patents could not be properly listed in the Orange Book unless the patents contained at lease one claim which claimed both the drug being administered and the medical device used to administer the drug. Teva asserted that Amneal’s proposed generic equivalent for its ProAir® HFA albuterol sulfate metered inhaler infringed 5 Teva inhaler patents listed in the Orange Book. Teva had previously received a warning letter from the FTC asserting it was engaging in unfair competition by listing the patents in the Orange Book because the listings triggered a 30 month stay of FDA approval of the ProAir® HFA generic.

Due to these and similar improper listings, aggrieved generic companies can bring antitrust actions for treble damages under the Sherman and Clayton Acts which may result in substantial treble damages. Brand name drug manufacturers can avoid this antitrust liability by updating their patent drafting practices to ensure at least one claim in combination medical device patents are directed towards both the active pharmaceutical ingredient and the device.

The webinar will discuss the history of how listing medical devices in the Orange Book occurred, best practices for drafting medical device patents, how medical devises can be properly listed if they are part of a combination drug, and how to possibly repair any improper listings.

To register for the March 5 - 10:30am EST, click HERE.

To register for the March 5 - 8:00pm EST, click HERE.

If you have any questions about registration, email marketingsupport@oblon.com.